Expert Discusses the Need for Safe and Effective Treatments for Aggressive Follicular Lymphoma

Video

Dr. Kami J. Maddocks discusses the importance of effective treatments for patients with aggressive follicular lymphoma and the treatment challenges they face.

While the National Institute of Health reports that follicular lymphoma has a five-year relative survival rate of 89%, follicular lymphoma has the potential to become aggressive, making it harder to treat, says Dr. Kami J. Maddocks.

In an interview with OncLive®, CURE®’s sister publication, Maddocks, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Comprehensive Cancer Center–James, examined the challenges that exist in treating patients with follicular lymphoma.

In particular, Maddocks noted, patients who relapse within 24 months of completing their first therapy tend to have a more aggressive disease, making it harder for oncologists to find treatments that will produce long-term results.

Follicular lymphoma that turns into aggressive, incurable lymphoma is another challenging issue, according to Maddocks. In these cases, allogeneic transplant is an option, but patients will need to be in treatment for the rest of their lives.

Transcription:

Probably our biggest challenge in patients with treating follicular lymphoma is those patients that we define as the early relapses. So those patients that progress within 24 months of completing their initial therapy, these patients have more aggressively behaved disease, and it's harder to get them long term responses and long-term remissions. This is the greatest challenge we face and there are ongoing trials right now looking at the best treatment for these patients.

When follicular (lymphoma) transforms to aggressive lymphoma, that also represents a challenge for patients. And then this is still you know, outside of an allogeneic transplant, which is rarely done not a curable disease. So, these are treatments, patients are going to deal with this disease on and off for the rest of their life. And so, finding effective, long-lasting and tolerable treatments is really a goal here.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE